Takeda hit with $885M pay-for-delay verdict over generic Amitiza delay. UCB's Bimzelx beats AbbVie's Skyrizi 49% vs 38% on ACR50 in PsA head-to-head. Trump bought up to $680K in Eli Lilly stock while admin promoted obesity drugs. Maryland caps Ozempic payments. Amgen Tavneos linked to 20 deaths in Japan. Relay zovegalisib Phase 2 data beats expectations.
Auto-generated from the episode script. Deal names link to their scorecard in the database.
A federal jury just handed Takeda an eight hundred eighty-five million dollar antitrust verdict — pay-for-delay on Amitiza — and it lands on a company already cutting forty-five hundred jobs.
Plus Bimzelx beats Skyrizi head-to-head in psoriatic arthritis, the president's personal Lilly trades raise conflict questions, and Maryland caps state payments for Ozempic. Full slate — let's get into it.
Welcome to The Pharma Closeout for Tuesday, May nineteenth, twenty twenty-six. I'm Alex Mercer.
And I'm Maya Patel.
Top story. A federal jury in Boston found Takeda liable for approximately eight hundred eighty-five million dollars in damages. Per Reuters, the jury concluded Takeda engaged in an anticompetitive scheme to delay a generic version of its constipation drug Amitiza — a pay-for-delay arrangement with a competitor to keep generic lubiprostone off the market.
Pay-for-delay cases have historically been among the hardest antitrust claims to win at trial. An eight hundred eighty-five million dollar award resets the risk calculus for every branded company sitting on an aggressive patent settlement. Juries are now willing to attach massive liability when generic entry is artificially blocked — that changes how legal teams model their next deal.
And the timing compounds it. Takeda is simultaneously executing forty-five hundred layoffs in its latest restructuring. Legal liability approaching a billion dollars stacked on an operational downsizing — that's not one problem, it's two problems reinforcing each other.
If this verdict survives appeal, expect accelerated FTC scrutiny of similar settlements across the industry. The political environment is already hostile to anything that looks like it kept prices elevated — yesterday the Supreme Court declined to even hear IRA challenges from six pharma companies. The door for pricing defenses keeps getting narrower.
Takeda will almost certainly appeal. Pay-for-delay liability remains legally contested, and the standards still have gray areas.
Even if the final number comes down, the message is in the market. Companies structuring their next patent settlement are pricing in this kind of jury exposure starting today.
The question is how far that exposure extends. Let's bring in Marcus Webb on this.
The eight hundred eighty-five million is one company's problem. The appellate outcome is the industry's. If this verdict stands, every pay-for-delay settlement signed in the last decade that hasn't expired becomes a potential litigation target. Downstream exposure across the sector dwarfs this single case.
And when you pair that with federal price negotiations surviving court review and antitrust juries attaching nine-figure penalties in the same week — every company that built growth assumptions around pricing power needs to revisit the math.
All right, shifting to the deal and pipeline side. The data driving the most conversation today came from UCB. In the BE BOLD trial — a substantial patient population, double-blinded over an extended timeframe — Bimzelx went head-to-head against AbbVie's Skyrizi in active psoriatic arthritis. Bimzelx won. Forty-nine percent of patients hit ACR50 at week sixteen versus thirty-eight percent on risankizumab. Eleven-percentage-point superiority margin on the primary endpoint.
Eleven points on ACR50 in a head-to-head is not subtle — and the endpoint choice matters. UCB went with ACR50, not ACR20. They bet on depth of joint response, and the delta held. Per UCB, this is the first licensed biologic to demonstrate superiority over an IL-23 inhibitor in PsA. The open question is whether rheumatologists shift prescribing the way dermatologists have in plaque psoriasis. AbbVie is building its post-Humira strategy on Skyrizi and Rinvoq — head-to-head superiority in PsA is exactly the kind of evidence that reshapes formulary conversations.
Staying in the pipeline — Relay Therapeutics posted initial Phase 2 data from the ReInspire trial of zovegalisib in PIK3CA-driven vascular anomalies. Per the company's announcement, the results demonstrate the advantage of PI3K-alpha mutant-selective inhibition. BioPharma Dive notes the therapy could be superior to Novartis's Vijoice in this space, and Endpoints reports the readout beat Wall Street expectations. Early data, but the orphan drug economics make even Phase 2 readouts commercially relevant.
Mutant-selective PI3K inhibition is the design principle to watch. If zovegalisib can separate efficacy from the class toxicity profile that's haunted this target for years, that tolerability edge becomes decisive in a disease where patients stay on therapy indefinitely.
Three quick hits to round out the segment. BioMarin's two hundred seventy million dollar bet on Inozyme's enzyme replacement therapy for ENPP1 deficiency hit trouble — the Phase 3 missed its primary endpoint and key secondaries, raising real doubts about the approval path. Roche signed a voluntary licensing deal with the Medicines Patent Pool to enable generic Xofluza manufacturing across a hundred twenty-nine low- and middle-income countries — pandemic preparedness infrastructure, built one license at a time. And Regeneron, coming off the fianlimab melanoma miss, locked in a hundred twenty-five million dollar Parabilis deal for hard-to-drug targets. When your IO combination strategy stalls, you double down on the discovery engine.
The BioMarin miss is the one to circle back to. Missing both primary and key secondary endpoints on a two hundred seventy million dollar acquisition narrows the regulatory path considerably. That was Inozyme's lead asset when BioMarin paid the premium — and the read-through to their broader rare disease strategy isn't encouraging.
On the regulatory front, three pricing stories converged today and they tell one story. KFF Health News reports President Trump earlier this year purchased as much as six hundred eighty thousand dollars in Eli Lilly stock — the maker of Zepbound and Mounjaro — while his administration was actively promoting obesity drugs through TrumpRx. Lilly, for what it's worth, also topped STAT's latest ranking of pharma innovators this week. That collision of personal financial interest and policy advocacy doesn't require much interpretation.
Separately, the TrumpRx platform added more than six hundred generic medications to its listings today. The White House frames it as expanding access — Endpoints calls it building on one success in US pricing. Fierce Pharma notes questions remain about the actual affordability impact, with caveats about how the platform functions in practice.
Then there's Maryland. The state's Prescription Drug Affordability Board voted to set an upper payment limit on Ozempic — the second drug the board has capped in recent weeks. Per Maryland Matters, the projected savings for state and local health plans run about five point eight million dollars a year. That number sounds modest in isolation. But the budget risk for Novo scales with every state that copies this model — we've been tracking state-level pricing pressure on the GLP-1 franchise, and Maryland just put a working template on the table. If a dozen states stand up similar boards, the cumulative drag on GLP-1 net pricing looks structurally different from isolated federal negotiation.
Federal negotiation survives Supreme Court review, state boards cap prices, antitrust juries impose nine-figure penalties, and the president personally holds equity in the largest beneficiary of obesity drug policy. The pricing convergence around this drug class just got considerably harder to dismiss.
Away from pricing — a drug safety story that demands attention. Reuters reports approximately twenty deaths linked to serious liver dysfunction in Japan among patients treated with Amgen's Tavneos for ANCA-associated vasculitis. The notice came from Japanese partner Kissei, which is now discouraging prescribers. Causality hasn't been definitively established, but twenty deaths against a relatively small treated denominator in a rare autoimmune population — the benefit-risk recalculation is already underway, and the question is whether regulators in the US and EU act before the Japanese investigation concludes.
And the institutional backdrop at FDA keeps shifting. BioPharma Dive reports Tracy Hoeg has been fired in the latest agency shakeup — the latest in a string of CDER departures we've been tracking. Meanwhile, hundreds of biotech executives and investors are campaigning for Rick Pazdur as the next commissioner. Leadership churn at the agency during an active PDUFA cycle isn't just a governance headline — it's a variable that touches every regulatory timeline on the board.
Looking ahead. The Novartis-Porton CDMO dispute deserves a follow. Novartis unilaterally terminated a plant contract with Chinese CDMO Porton and is threatening significant legal claims. Porton warns an unfavorable outcome could materially impact its twenty twenty-six financials — another thread in the China supply chain decoupling narrative. Separately, Aardvark Therapeutics saw its Prader-Willi drug placed on FDA clinical hold over safety concerns — a possible study unblinding could reshape the entire development program. And on the financing side, Israel-based Tarsier Pharma set IPO terms today — looking to raise forty-five million dollars for its steroid-free ocular disease pipeline. Small, but another sign the biotech IPO window remains open.
And the FDA May calendar still has live decisions pending — argenx's VYVGART label expansion, Daiichi Sankyo and AstraZeneca on an additional Enhertu indication, Eisai's Leqembi supplemental BLA, and MannKind's Afrezza pediatric application. Given the leadership instability Alex just flagged, the question isn't just what gets decided — it's whether the decision-making cadence itself holds.
That's your Pharma Closeout for Tuesday. Takeda staring down an eight hundred eighty-five million dollar antitrust reckoning, Bimzelx clearing the superiority bar over Skyrizi in PsA, BioMarin's rare disease miss putting a two hundred seventy million dollar bet in question, Roche opening Xofluza across a hundred twenty-nine countries, and the pricing net tightening around obesity drugs from every angle. If this briefing saves you time, follow us on Spotify, Apple Podcasts, or wherever you listen — and drop a rating while you're there. We're back tomorrow.
Enjoy your Tuesday evening. See you tomorrow.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →